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Why is it that so many organ recipients, especially re-cipients of a liver, are able to survive without taking 
immunosuppressive drugs? The first recipient of a 
liver at Baylor, Amie Garrison, was 5 years old at the time of her 
transplantation in 1984. When she was age 15, however, she 
rebelled and refused to continue taking her medication. We 
feared the worst, but happily she has survived off drugs for more 
than 5 years. Furthermore, she is now married and has a young 
child of her own. What happened? 
Survival without immunosuppressive medication is not un-
common. Indeed, at our clinic in Pittsburgh we deliberately wean 
liver transplant recipients from immunosuppressive therapy un-
der close supervision (1, 2 )-quite a different situation than 
noncompliance. We believe that patients who can survive with 
stable graft function off immunosuppressive therapy have genu-
ine immunological donor-specific tolerance and can anticipate 
a normal life expectancy. 
Another dramatic case also illustrates my point. Approxi-
mately 13 years ago, a child from a prominent Eurasian family 
became ill on a flight from Hong Kong to Manila. She had a 
hepatoma of the liver which ruptured, causing a nearly fatal 
hemorrhage. Her family had the plane rerouted to Los Angeles 
and from there to Pittsburgh, where we performed a liver trans-
plantation. Tumor from the lesion was thought to have seeded 
throughout the abdomen. The prognosis appeared hopeless. 
Postoperatively, the child received chemotherapy, and after 
a stormy course that included a bout of severe pancytopenia, she 
returned home and grew up. She not only stopped taking immu-
nosuppression medication but also became a fashion cover girl 
and is now on her way to becoming a world-class ballet dancer 
(as was her mother before her). Like Amie Garrison, this patient 
has a normal life expectancy. She has acquired tolerance. 
Although it was not recognized as such, tolerance has been 
a theme throughout the entire modern age of organ transplanta-
tion. This was belatedly acknowledged at a meeting last March 
at the University of California, Los Angeles (UCLA). The pur-
pose of the conference was to reach a consensus about the mile-
stones that had made transplantation a thriving clinical specialty. 
Eleven early workers in clinical organ and tissue transplantation 
contributed to the program. Professor Carl Groth (Karolinska In-
stitute, Stockholm) was invited to be chairman of the consensus 
deliberations, the conclusions from which are being published (3). 
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The participants included histocompatibility specialists Jean 
Dausset, MD, Paul Terasaki, PhD, and Jon J. Van Rood, MD; 
early investigators of acquired tolerance (Leslie Baruch Brent, 
PhD) and drug immunosuppression (Robert S. Schwartz, MD); 
bone marrow transplanters Robert A. Good, MD, and E. Donnall 
Thomas, MD; and organ transplant surgeons Roy Caine, MD, 
Joseph E. Murray, MD, Norman E. Shumway, MD, and myself. 
The 4 surgeons accounted for the first successful transplan-
tations of the kidney, liver, and heart. Murray became a 1990 
Nobel laureate. Good performed the first successful bone marrow 
transplantation in 1968. Thomas was a Nobel laureate in 1990 
for his studies of bone marrow transplantation for a variety of 
diseases. Leslie Brent is the Brent of the famous British team 
known in the 1950s as the "holy trinity" of transplantation im-
munology. Schwartz was the first to show the immunosuppressive 
qualities of 6-mercaptopurine (6-MP) and azathioprine (4). For 
his discovery of the first human histocompatibility locus antigen 
(HLA) (5), Dausset received a Nobel prize. Terasaki and Van 
Rood introduced tissue matching into clinical transplantation. 
MILESTONES VS TURNING POINTS 
Milestones 
The participants placed transplantation milestones in 2 cat-
egories (Table 1). The first consisted of generic advances that 
were applicable to all kinds of allografts. Progressively more ef-
fective immunosuppressive agents and drug regimens headed this 
list. Methods of tissue and organ preservation and histocompat-
ibility matching also qualified. Although broadly applicable sur-
gical techniques were not listed, they could be exemplified by 
the development nearly 100 years ago by Alexis Carrel of tech-
niques for vascular surgical anastomoses (6). 
The second category of milestones was organ- or cell-
specific. This consisted of the first examples of long allograft and 
patient survival E;~S months) after transplantation of various 
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Table 1. Transplantation milestones 
I. Generic milestones (applicable to all tissues and organs) 
A. First use of individual immunosuppressants (all eventually combined with 
adrenal cortical steroids) 
1. Total body irradiation (1959) 
2. 6-MP and azathioprine (1960-1962) 
3. Other myelotoxic agents (1960-1965) 
4. Adrenal cortical steroids (anecdotally, 1955-1961; systematically, 
1962-1963) 
5. First effective tolerance-inducing cocktail (azathioprine/prednisone) 
(1962-1963)* 
6. Antilymphoid antibodies (antilymphocyte globulin) (1966) 
7. Cyclosporine (1978-1979) 
8. Tacrolimus (1989) 
B. Tissue and organ preservation 
1. Hypothermia per se 
(a) Surface cooling (1960) 
(b) Cold fluid infusion (1962-1963) 
2. Special infusates; slush preservation 
(a) Lactated Ringer's solution (1962-1963) 
(b) Low-molecular-weight dextran (1963) 
(c) Mimicking intracellular composition (1966) 
(d) Mimicking extracellular composition (1973) 
(e) UW solution (1987) 
3. Artificial postmortem circulation 
(a) Whole cadaver (1963) 
(b) Isolated organ (196W 
C. Clinical histocompatibility matching 
1. Lymphocyte culture LMLR (1963) 
2. Serologic (1964) 
3. Molecular (1990s) 
II. Generic clinical milestones (tissue- or organ-defined milestones: first clinical 
survival >6 months) 
A. Kidney 
1. Isografts (1954) 
2. Allografts (1959) 
B. Bone marrow 
1. Isografts (1955) 
2. Allografts (1963, 1968) 
C. Extrarenal organs 
1. Liver (1967) 
2. Heart (1968) 
3. Lung (1968) 
4. Pancreas (1969) 
5. Intestine (in multivisceral grafts, 1987; segmental, 1988; complete, 
1989) 
*Generic strategy applicable with subsequent drugs. 
tFirst experiments by A. Carrell and C. A. Lindberg (1935). 
kinds of human tisslies and organs. This objective was accom-
plished with the kidney in January 1959 (7), and with the liw\" 
(8), heart (9), lung (10), and pancreas (11) in that order between 
July 1967 and June 1969. Completely successful bone marrow 
transplantation was not done until 1968 (12, 13), and intesti-
nal transplantation was delayed until the late 1980s. 
Turning points 
The foregoing milestones in both generic and organ-specific 
categories, and dozens of lesser ones, afe important. However, as 
the layers of history were peeled away it became apparent that 
there actLlally were only 2 seminal turning points in the evolu-
tion of clinical transplantation: that allograft tolerance can be 
acquired and that organs are inherently tolerogenic (14-16). The 
stage for these turning points had been set during the Second 
World War with the demonstratiun by Medawar (a basic scien-
tist) and Gibson (a plastic surgeon) that rejection is an immune 
response (17). However, rejection was considered for the ensu-
ing decade to be one of the most powerful and irrevocable reac-
tions in biology and therefore uncontrollable. 
The resulting pessimism about the prospects of clinical trans-
plantation had to be modified in 1953 when Billingham, Brent, 
and Medawar demonstrated the induction of chimerism-
associated acquired neonatal tolerance (18). This was the first 
turning point. The tolerance induced in neonatal mice with sple-
nocyte or bone marrow cell infusion mimicked the natural hema-
tolymphopoietic chimerism in freemartin cattle reported nearly 
a decade earlier by Owen (19). The neonatal mouse experiments 
escalated in a straight line to clinical bone marrow transplanta-
tion (12, 13, 20). 
The second turning point was the clinical demonstration in 
the early 1960s that tissue and organ allografts could "self-induce" 
tolerance when combined with immunosuppression (21). This 
discovery galvanized a revolution in clinical organ transplanta-
tion. The downside, however, was the erroneous conclusion that 
the "acceptance" and long-term survival of organs occurred by dif-
ferent mechanisms than the chimerism-dependent tolerance in-
duced by bone marrow and other hematolymphopoietic allografts. 
The ostensible differences between hone marrow transplan-
tation and organ transplantation (Figure I) seemecl too great to 
permit any other conclusion. These differences included 1) de-
pendence on HLA matching for successful hune marrow trans-
plantatiun but not for organ transplantation, 2) risk vs freedom 
of risk from graft-vs-host disease (C3VHD), 3) frequency vs in-
frequency of achievement of drug-free status, and 4) a semantic 
distinction between the tolerance of bone marrow transplanta-
tion and the acceptance of organ grafts. 
As it turned out, all of these differences were explained by 
hematopoietic cytoablation of the bone marrow recipient (ini-
tially with total body irradiation, later with cytotoxic drugs) but 
not of the organ recipient. When this finally was recognized in 
the 1990s, the linkage between organ transplantation and bone 
marrow transplantation was established. In addition, the relation 
of hoth varieties of transplantation to the neonatal tolerance 
described by Billingham, Brent, and MedawaT was ll[,vious. The 
epiphany was largely dependent un the demonstration of low-
level donor leukocyte chimerism in livLT allograft recipients (14-
16). Consequently, it will be useful here to review how liver 
transplantation evolved. 
THE LATE 1950s 
Turning the clock back more than 40 years, my personal 
involvement in transplantation began with the development in 
1958 and 1959 of techniques for canine liver transplantation, 
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Figure 1. The division of transplantation into two separate disciplines, 
caused by different treatment policies. 
alone or as part of multivisceral grafts (22,23), paralleling simi-
lar independent investigations in Boston by Francis D. Moore 
(24). This was at first an exercise in surgical technique. Although 
adrenal cortical steroids and total body irradiation were known 
to be immunosuppressive, survival for as long as 3 months had 
not been achieved in any species with any kind of organ allograft. 
Our laboratory efforts took on a different meaning with the 
demunstration in 1959 by Schwartz and Damashek (4, 25), 
promptly confirmed by Good's Minnesota team (26), that 6-MP 
prolonged the survival of skin grafts in rabbits without the need 
for the kind of bone marrow depression caused by irradiation. 
When in 1960 CaIne in London (27) and Zukoski in Richmond, 
Virginia (28), reported that 6-MP therapy prolonged kidney al-
lograft survival in dogs, the possibility of similarly treating liver 
recipients was obvious. In fact, this was attempted clinically less 
than 3 years later, following advances with immunosuppression 
made in human kidney recipients. 
THE PATHFINDER KIDNEY 
Between January 26, 1959, and March 1, 1963, the date of 
our first attempt to replace a human liver, Murray in Boston (7) 
and the French teams of Hamburger (29) and Kuss (30) had pro-
duced 6 clinical examples of kidney allograft survival exceeding 
6 months after pretreatment with total body irradiation (Table 
2). Although 4 of these patients soon died, the 2 recipients of 
fraternal twin kidneys survived more than 20 years. Importantly, 
the seventh kidney recipient was 11 months posttransplantation 
by March 1, 1963, after treatment by Murray from the outset 
(April 1962) with the 6-MP analogue azathioprine (31). This 
allograft functioned for l7 months. 
It had been learned, however, that to achieve more than 
occasional success in either dogs or humans, azathioprine needed 
a partner drug. This proved to be dose-maneuverable prednisone 
(21), which we knew from our canine kidney and liver transplant 
studies could reverse 90% of the rejections developing under 
azathioprine. Unbeknownst to us, this steroid effect already had 
Table 2. Kidney transplantation::::6 months survival as of March 1963 
Case City Date Donor Survival (months)' 
Bostont 1-24-59 Frat twin >50 
2 Paristt 6-29-59 Frat twin >45 
3 Paris 6-22-60 Unrelated§ 18 (died) 
4 Paris 12-19-60 Mother§ 12 (died) 
5 Paris 3-12-61 Unrelated§ 18 (died) 
6 Paris 2-12-62 Cousin§ >13 
7 Boston 4-5-62 Unrelated 11 
* The kidneys in patients 1,2, and 6 functioned for 20.5, 25, and 15 years, respectively. 
Patient 7 rejected his graft after 17 months and died after return to dialysis. 
t Boston: J. E. Murray (1 and 7). 
It Paris: J. Hamburger (2, 4, and 6); R. Kuss (3 and 5). 
§ Adjunct steroid therapy. 
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Figure 2. Historical view of events after successful organ transplanta-
tion: rejection, its reversal, and the development of donor-specific 
nonreactivity. 
been seen in the autumn of 1960 by Willard Goodwin in a kid-
ney recipient at UCLA in whom bone marrow depression had 
been induced with myelotoxic doses of methotrexate and cyclo-
phosphamide (32). Regrettably, the case was not reported until 
1963, by which time the pioneer UCLA program had closed 
down because of the early deaths of all the other recipients. 
In the meanwhile, we had begun our clinical kidney trans-
plant program in the autumn of 1962, using azathioprine plus 
prednisone. As reported in October 1963 (21), 8 of our first 10 
kidney recipients had prolonged graft survival. This was the first 
successful series of kidney transplantations. Two of these patients, 
now old men in their 37th posttransplant year, bear the longest 
continuously functioning allografts in the world. As has been ex-
pected from the observations in dogs, rejection was regularly re-
versible. More importantly, there was also clear evidence that the 
transplanted kidneys had self-induced variable donor-specific tol-
erance. 
The most convincing evidence of tolerance was the frequent 
diminution of need for maintenance immunosuppression after 
the development of rejection and its reversal (Figure 2). The 
donor-specific nonreactivity was complete enough to allow many 
patients to go home to an unrestricted environment. The third 
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Figure 3. The 3 eras of orthotopic liver transplantation at the Univer-
sities of Colorado (1963-1980) and Pittsburgh (1981-1993), defined 
by azathioprine, cyclosporine, and tacrolimlls (FK 506)-based immune 
suppression, Similar but less dramatic stepwise improvement has been 
seen with all organs. Top family of curves: patient survival. Bottom fam-
ily: graft survival. 
patient in this series stopped all medications about 1 year after 
transplantation and has heen drug free for more than a third of 
a century (33). 
LIVER TRANSPLANTATION 
Our early experience with kidney transplantation, combined 
with more than 5 years' investigation of canine liver transplan-
tation, prompted our attempts to replace the human liver, the first 
vital extrarenal organ to be transplanted clinically. When the first 
3 patients (34), single patients in Boston (35) and Paris (36), and 
an additional 2 recipients in our Colorado program (37) all died 
within 23 posttransplant days, clinical liver transplantation ceased 
worldwide. During the 3 1/2-year self-imposed moratorium, we 
developed and introduced horse antihuman antilymphocyte 
globulin clinically, first testing it in kidney recipients as a 
perioperative adjunct to azathioprine and prednisone (38). 
Armed with the encouraging results in the kidney trial, the 
liver program was restarted in July 1967, using the same 3-drug 
immunosuppression (azathioprine, prednisone, and antilympho-
ctye globulin) that had been tested in kidney recipients. A num-
ber oflong survivals were obtained (> 1 year), mostly of children 
(39). A 33-year-old woman (then a 3-year-old child with biliary 
atresia and a hel'atuma) is the longest surviving liver recipient 
in the world, now in her 30th posttransplant year. 
Another 13 years would pass before this kind of result be-
came regularly attainable. The improvement in transplantation 
of the liver and other organs has occurred in 3 distinct drug-
Table 3. Central therapeutic dogma 
1. Baseline therapy with one or two drugs' 
2. Secondary adjustments with steroids or al1tilymphoid agents 
3. Case-to-case trial (and potential error) of weaning 
*Baseline agents: azathioprine, cyclophosphamide, cyclosporine, cyclosporine-
azathioprine, FK 506, FK S06-azathioprine. 
defined eras: azathioprine-based therapy, cyclosporine-based 
therapy (40, 41), and tacrolimus (FK 506) (42) (Figure 3). Be-
cause retransplantation became increasingly more reliable with 
the better immunosuppression, patient survival was successively 
better than graft survival. With the advent of tacrolimus, the first 
immunosuppressant to be evaluated primarily with liver trans-
plantation, intestinal transplantation hecame a viable clinical 
option. 
EXPLANATION OF "ORGAN ACCEPTANCE" 
Despite the diversity of azathioprine, cyclosporine, tacro-
linms, and other immunosuppressants, the basic pattern of im-
munologic confrontation and involution remained the same. 
With individualized treatment adjustments guided by evidence 
of graft rejection, graft acceptance could be engineered as de-
scribed in Table 3. What was being accomplished with this strat-
egy? The answer was discovered in 1992. 
In the spring of 1992, 25 liver and 5 kidney recipients who 
had survived with functioning grafts for 10 to 30 years were 
brought to Pittsburgh for restudy. In addition to blood sampling, 
open biopsy was obtained of the transplanted organs; of the re-
cipient lymph nodes and skin; and, when indicated, of other host 
organs, including the heart, intestine, and bone marrow. Small 
numbers of donor leukocytes were found in the host peripheral 
lymphoid and nonlymphoid tissues or blood of all 30 patients (14, 
15). The donor cells were identified by study of the HLA anti-
gens or sex karyotype with immunocytochemical methods. The 
findings were confirmed with polymerase chain reaction studies. 
The chimerism included the prominent presence of dendritic 
cells. 
Now, we realized that organ transplantation involved a 
double immune reaction-which had both a host-vs-graft re-
sponse and a covert graft-vs-host response (Figure 4). Because the 
dominant imrntme reaction following organ transplantation usu-
ally is that of the host, the common complication is rejection of 
the graft. However, serious or lethal GVHD is not rare after trans-
plantation of leukocyte-rich organs like the liver. For allograft 
acceptance (and tolerance) to occur (rather than rejection or 
GVHD), the seminal tolerogenic mechanism was postulated to 
be "[widespread] responses of coexisting donor and recipient im-
mllne cells, each to the other, causing reciprocal clonal expan-
sion, followed by peripheral clonal deletion" (14, 15). 
By 1998, compelling evidence had accumulated from con-
trolled animal experiments confirming this hypothesis, as sum-
marized in a recent review coauthored with Rolf Zinkernagel 
(16). Organ and bone marrow "acceptance" were related forms 
of acquired tolerance-not fundamentally different than the 
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that occur after transplantation. Treatment failure is defined as the 
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Figure 5. The 4 events that occur in close temporal approximation 
when there is successful organ engraftment: ahovt:', double acute clonal 
exhaustion (numbers 1 and 2) and subsequent maintenance clonal 
exhaustion (3) plus, below, loss of organ immunogenicity due to deple-
tion of the graft's passenger leukocytes (4). 
major histocompatibility (MHC)-restricted antigen-specific tol-
erance that can be induced by non cytopathic viruses and other 
microorganisms (16). However, the response to an organ allograft 
is made more complex than that to a noncytopathic microorgan-
ism by the presence of immunocompetent donor cells and the 
consequent double immune reaction (graft vs host as well as host 
vs graft). 
Clonal exhaustion and an ancillary mechanism of "immune 
indifference," both regulated by the migration and localization 
of the donor leukocytes, were responsible for the 4 interrelated 
events shown in Figure 5. These must occur in close temporal 
proximity for successful organ engraftment: double acute clonal 
exhaustion; maintenance clonal exhaustion, which waxes and 
wanes; and loss of organ immunogenicity as the passenger leu-
kocytes depart from the graft. 
The reciprocal nullification of the interreactive immune re-
sponses explained the poor prognostic value of tissue matching 
for organ transplantation (43). This nullification effect also ex-
Table 4. Effectors involved in response to cytopathic parasites and 
discordant xenografts 
The first line of defense 
Interferons 
M acrophages 
y /8 T cells 
Natural killer (NK) cells 
B cells 
Nonspecific or less specific effectors 
Complement 
Early interleukins 
Phagocytes 
iii 
plains why GVHD is so uncommon, even after organ transplan-
tation with engraftment of leukocyte-rich organs like the liver and 
intestine, and why it is safe to infuse adjunct donor bone marrow 
in organ recipients providing the patients are not immunologically 
weakened in advance by cytoablation or other means (15, 33). 
It follows that conventional bone marrow transplantation 
is a mirror image of the events after organ transplantation and 
is also governed by antigen migration and localization. The host 
leukocytes are not all eliminated by pretransplant cytoablation 
(44, 45). The weak host-vs-graft reaction mounted by those re-
maining recipient cells and the parallel graft-vs-host reaction of 
the dominant population of donor cells can eventually result in 
reciprocal tolerance (16,46). It might be added that these same 
events transpire in the historically important "mixed chimerism" 
tolerance models. We had in fact returned full circle to the first 
observations of natural tolerance in freemartin cattle reported 
in Science 55 years earlier by Ray Owen ( 19). 
XENOTRANSPLANTATION 
There is no MHC-restricted safety valve for cytopathic mi-
croorganisms, which arc typically extracellular and generate the 
full resources of the innate as well as the adaptive immune sys-
tem (16, 47, 48). An uncontrollable innate immune response 
involving the effectors shown in Table 4 is provoked by discor-
dant xenografts expressing the Cal-a Cal epitope, an epitope 
that is also found on numerous cytopathic bacteria, protozoa, and 
viruses. The clinical use of such discordant animal donors (e.g., 
pigs) will require either changing the xenogeneic epitope to one 
that mimics a noncytopathic profile or eliminating the xenoge-
neic epitope (16,49). 
SUMMARY 
Thus, the 2 seminal turning points that allowed the clini-
cal emergence of transplantation turned out to invoke the same, 
not different, tolerance mechanisms. This has explained histori-
cal enigmas, including the meaning of allograft acceptance, 
which is simply a form of acquired tolerance. This paradigm also 
establishes a better context for the design of experiments and 
therapies yet to come. 
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